PLX4032 (Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors.
上海蓝木化工有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!